Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alibaba

Darling Ingredients

Evotec SE

MGP Ingredients

Sociedad Quimica Y Minera De Chile

Triple Flag Precious Metals Corp

The seven stable stocks discussed below each have the potential to double by 2025 based on analyst target prices. Each of the seven stocks is also relatively stable based on the fact that none have a beta higher than 1.4.

7 Stable Stocks to Buy for 100% Returns by 2025

Pan American Silver

Perrigo

Underdogs stocks carry almost universal appeal. It's one thing to go with the rest of the crowd.

Hidden Gems: 3 Market Underdogs to Buy at Rock-Bottom Prices

Palo Alto Networks

Simon Property Group

The STOCK Act of 2012 was supposed to halt insider trading by members of Congress, but let's be honest. The STOCK Act can't really stop Congresspeople from trading on insider knowledge; they're in a position to get it, which will influence investment decisions.

3 Hot Stocks Bought by Members of Congress: Follow the Money

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States. The Riskguard test provides an individualized patient report that includes gene specific and familial risks using a simple blood or saliva sample for 10 common cancers, including colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine. “Riskguard is.

Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United States

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. TD Cowen 44th Annual Health Care Conference, Boston Fireside chat on Monday, March 4, 2024 at 1:30 p.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact S.

Exact Sciences to Participate in March Investor Conference

Robust revenues from Exact Sciences' (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.

Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y

Exact Sciences Corporation (EXAS) Q4 2023 Earnings Call Transcript

Exact Sciences (EXAS) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.72 per share a year ago.

Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $647 million for the fourth quarter of 2023 and $2.50 billion for the full year of 2023, both ended Dec. 31, 2023. “The Exact Sciences team advanced our mission to help eradicate cancer by testing a record number of patients with Cologuard® and Oncotype DX® in the fourth quarter, leading to strong financial result.

Exact Sciences Announces Fourth Quarter 2023 Results

Exact Sciences' (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer screening tests, Cologuard and Oncotype DX.

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

Exact Sciences' cancer testing platform continues to succeed and expand. However, the company remains unprofitable and has to contend with stiff competition.

Cathie Wood Is Selling This Stock: Should You?

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the U.S. financial markets on February 21, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Fourth quarter 2023 webcast & conference call details Date.

Exact Sciences Schedules Fourth Quarter 2023 Earnings Call

Guardant Health Inc

Illumina

I'm bullish on the long-term trajectory of personalized medicine stocks. These companies specialize in tailoring a holistic approach to healthcare, with medical treatments tailored to the individual characteristics of each patient.

3 Stocks to Buy for the Age of Personalized Medicine

Exact Sciences reported a 17% increase in total revenue in Q4 2023, driven by the Screening and Precision Oncology segments. The company's innovative products, such as Cologuard and Oncotype DX, are reshaping cancer screening and treatment paradigms. Exact Sciences' strategic focus on research and development, including the development of next-generation products, positions it for future growth and success in the oncology market.

Exact Sciences: Growing Revenue With An Innovative Approach To Oncology

Quest Diagnostics

Labcorp Holdings Inc

Stocks such as EXAS, DGX and LH are likely to potentially continue the momentum in the oncology field.

Oncology Space Gains Momentum: 3 Stocks in Focus

Block

Exact Sciences and Block are both among Cathie Wood's top picks. Exact Sciences' work in cancer detection is proving lucrative, with plenty of room left for growth.

2 Cathie Wood Growth Stocks to Buy and Hold for the Long Haul

Blood tests for dozens of types of cancer have been invented. These tests, known as liquid biopsies, could save tens of millions of lives.

The Top 3 Stocks in the High-Potential ‘Cancer Testing' Market

Amicus Therapeutics

Hologic

The new year brings a clean slate heading into the fourth-quarter earnings season. Companies can usually gauge if their previous forecasts were in line or need to be adjusted to warn or prepare investors ahead of time.

Time to buy these 3 healthcare companies that raised revenue guidance?

ST. LOUIS, Mo.--(BUSINESS WIRE)--Geneoscopy Files Inter Partes Review Petition Challenging Exact Sciences' Patent.

Geneoscopy Files Inter Partes Review Petition Challenging Exact Sciences' Patent

Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, submits next-generation Cologuard® to FDA Announces Chief Financial Officer succession plan Highlighted announcements: Expects total fourth quarter revenue of $645.5-$647.5 million, an increase of 17% compared to the fourth quarter of 2022, with Screening revenue of $486.0-$487.0 million and Precision Oncology revenue of $159.5 - $160.5 million Expects total full-year 2023 revenue of $2.50 billion and 2024 revenue of $2.83 billion Submitted final module of next-generation Cologuard premarket approval application to FDA Announces Jeff Elliott plans to step down as Executive Vice President and Chief Financial Officer MADISON, Wis. , Jan. 7, 2024 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue between $645.5 million and $647.5 million for the fourth quarter ended December 31, 2023.

Exact Sciences Announces Preliminary Fourth Quarter 2023 Results

MADISON, Wis. , Jan. 2, 2024 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

Exact Sciences to participate in J.P. Morgan Healthcare Conference

Cardinal Health

Haemonetics

Penumbra

Insulet

Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.

5 Impressive MedTech Industry Growth Stocks to Buy for 2024

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.

Exact Sciences' (EXAS) Solid Cologuard Sales, Innovation Aid

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

Vertex Pharmaceuticals

Healthcare stocks rarely outperform the S&P 500 over long periods. Exact Sciences and Vertex Pharmaceuticals have been two of the rare exceptions over the prior 10 years.

News for Exact Sciences Stock (EXAS)